PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19669298-7 2008 Peg IFN-alpha treatment in non-responders to lamivudine or adefovir dipivoxil showed similar response rate to that seen in naive patients. Lamivudine 45-55 interferon alpha 1 Homo sapiens 4-13 25911883-7 2015 CONCLUSIONS: Our present meta-analysis suggests that different types of IFN-a in combination with LAM can significantly reduce the rate of YMDD mutation compared to LAM monotherapy. Lamivudine 165-168 interferon alpha 1 Homo sapiens 72-77 21940341-9 2011 In the LAM+IFN group, resistance to lamivudine was significantly lower in the first 24 months of treatment, reaching 72% by 84 months. Lamivudine 36-46 interferon alpha 1 Homo sapiens 11-14 21319036-0 2010 Non-response to previous interferon therapy and cirrhosis are risk factors for predicting breakthrough during lamivudine therapy in patients with chronic hepatitis B. Lamivudine 110-120 interferon alpha 1 Homo sapiens 25-35 21186536-1 2010 OBJECTIVE: To observe the efficacy and safety of PEG-interferon alpha-2a (PEG-IFNalpha-2a) treatment on lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients. Lamivudine 104-114 interferon alpha 1 Homo sapiens 78-86 21186536-1 2010 OBJECTIVE: To observe the efficacy and safety of PEG-interferon alpha-2a (PEG-IFNalpha-2a) treatment on lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients. Lamivudine 116-119 interferon alpha 1 Homo sapiens 78-86 21186536-8 2010 CONCLUSION: PEG-IFNalpha-2a treatment of lamivudine-resistant HBeAg (+) chronic hepatitis B is superior to ADV, and its security is well. Lamivudine 41-51 interferon alpha 1 Homo sapiens 16-24 26584037-3 2015 In this paper, the aim was to assess: (1) the long-term efficacy and safety as well as the resistance to ETV and tenofovir disoproxil fumarate (TDF); (2) the efficacy of PEG IFN-alpha; (3) the role of combination therapy with IFN plus two analogues, such as lamivudine and ETV; (4) the efficacy and safety of two analogues with cirrhosis, and (5) suppression of hepatocellular carcinoma (HCC) by ETV and IFN treatment. Lamivudine 258-268 interferon alpha 1 Homo sapiens 174-177 18364079-3 2008 Lamivudine was administered to 35 patients for 48 weeks, sequential therapy with lamivudine-IFN alpha-2b to 24 of the 71 patients for 48 weeks, and interferon alpha (IFN alpha-2b) was administered to 12 for 24 weeks. Lamivudine 81-91 interferon alpha 1 Homo sapiens 92-101 18364079-14 2008 CONCLUSIONS: Both 48 weeks of sequential lamivudine-IFN alpha and lamivudine monotherapy strongly reduced intrahepatic HBV DNA and cccDNA more than 24 weeks of IFN alpha monotherapy. Lamivudine 41-51 interferon alpha 1 Homo sapiens 52-61 18364079-14 2008 CONCLUSIONS: Both 48 weeks of sequential lamivudine-IFN alpha and lamivudine monotherapy strongly reduced intrahepatic HBV DNA and cccDNA more than 24 weeks of IFN alpha monotherapy. Lamivudine 41-51 interferon alpha 1 Homo sapiens 160-169 18364079-14 2008 CONCLUSIONS: Both 48 weeks of sequential lamivudine-IFN alpha and lamivudine monotherapy strongly reduced intrahepatic HBV DNA and cccDNA more than 24 weeks of IFN alpha monotherapy. Lamivudine 66-76 interferon alpha 1 Homo sapiens 160-169 16688836-0 2006 Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. Lamivudine 76-86 interferon alpha 1 Homo sapiens 10-13 17958644-3 2007 Better results have recently been reported with pegylated IFN both in IFN-naive and in previous nonresponders to standard IFN, suggesting the use of pegylated IFN as a first-line therapy in chronic hepatitis D. Nucleoside analogues that inhibit hepatitis B virus (HBV) are ineffective against HDV and combination therapy with lamivudine or ribavirin has not shown significant advantages over monotherapy with either standard or pegylated IFN. Lamivudine 326-336 interferon alpha 1 Homo sapiens 58-61 17716343-10 2007 In Australia and Poland, lamivudine-preferred strategies dominated interferon (IFN)-alpha and its related strategy from the health-care sector perspective. Lamivudine 25-35 interferon alpha 1 Homo sapiens 67-89 17244247-9 2007 Patients treated with pegylated IFN-alpha-2a, either as monotherapy or in combination with LAM, showed significantly reduced HBV DNA levels compared with patients treated with LAM monotherapy. Lamivudine 91-94 interferon alpha 1 Homo sapiens 32-41 17226901-1 2007 AIM: To characterize the IFN-response and its modulation by the antiviral compound lamivudine in HBV-transfected HepG2.2.15 cells. Lamivudine 83-93 interferon alpha 1 Homo sapiens 25-28 17029610-0 2006 Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Lamivudine 111-121 interferon alpha 1 Homo sapiens 29-39 17029610-9 2006 CONCLUSIONS: Peg-IFN alpha2b is effective in approximately one-third of patients who failed to respond to previous treatment with standard IFN or lamivudine. Lamivudine 146-156 interferon alpha 1 Homo sapiens 17-20 16688836-1 2006 AIM: To investigate the role of pegylated-interferon (IFN) alpha-2b in the management of patients with lamivudine-resistant chronic hepatitis B. Lamivudine 103-113 interferon alpha 1 Homo sapiens 32-58 16118673-13 2005 Lamivudine, on the other hand, may be more suitable for patients with cirrhosis, non-responders to IFN-alpha or in cases with contraindication for IFN-alpha. Lamivudine 0-10 interferon alpha 1 Homo sapiens 99-108 16568374-7 2006 LAM (10mg/day during 1 year) was started when IFN withdrawal hepatitis occurred during 2-10 months after stopping IFN. Lamivudine 0-3 interferon alpha 1 Homo sapiens 46-49 16568374-7 2006 LAM (10mg/day during 1 year) was started when IFN withdrawal hepatitis occurred during 2-10 months after stopping IFN. Lamivudine 0-3 interferon alpha 1 Homo sapiens 114-117 16171525-7 2005 CONCLUSION: In conclusion, our study suggest that BMD of femur, serum IL-2r, IL-6, IL-8, PTH, and CTX levels were higher in children with chronic hepatitis B treated with IFN-alpha alone or combination with lamivudine than in healthy children. Lamivudine 207-217 interferon alpha 1 Homo sapiens 171-180 16118673-13 2005 Lamivudine, on the other hand, may be more suitable for patients with cirrhosis, non-responders to IFN-alpha or in cases with contraindication for IFN-alpha. Lamivudine 0-10 interferon alpha 1 Homo sapiens 147-156 16108170-10 2005 There is a tendency for IFN-a and lamivudine combination to result in better sustained response than lamivudine monotherapy. Lamivudine 101-111 interferon alpha 1 Homo sapiens 24-29 14635007-11 2004 It is suggested that lamivudine-induced seroconversion differs from spontaneous or IFN-induced seroconversion in the change of nucleotides in the precore region. Lamivudine 21-31 interferon alpha 1 Homo sapiens 83-86 15078472-1 2004 BACKGROUND/AIMS: Hepatitis B e antigen-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B (CHBe-) exhibits a high relapse rate on monotherapy with lamivudine or interferon-alpha (IFN-alpha). Lamivudine 162-172 interferon alpha 1 Homo sapiens 194-203 15720534-2 2005 We investigated whether priming lamivudine treatment might enhance the antiviral and immunostimulant action of lamivudine/IFN combination in young tolerant patients. Lamivudine 32-42 interferon alpha 1 Homo sapiens 122-125 15720534-6 2005 After IFN withdrawal, viraemia transiently increased to high levels in five of 11 (45%) patients who showed rt M204V/I lamivudine mutant resistant. Lamivudine 119-129 interferon alpha 1 Homo sapiens 6-9 15610309-2 2004 In this study, we investigated the effects of alpha-interferon (IFN-alpha) combined with lamivudine on the occurrence of viral breakthrough during long-term lamivudine therapy. Lamivudine 157-167 interferon alpha 1 Homo sapiens 64-73 15610309-9 2004 CONCLUSION: IFN-alpha combined with lamivudine may reduce viral breakthrough during long-term lamivudine therapy, probably by suppressing the appearance of YMDD mutants. Lamivudine 94-104 interferon alpha 1 Homo sapiens 12-21 15504288-9 2004 It is also more economical than a combined therapy of lamivudine with IFN. Lamivudine 54-64 interferon alpha 1 Homo sapiens 70-73 15504288-10 2004 CONCLUSION: This sequence administration of lamivudine and IFN pattern can significantly improve the anti-virus effect on HBV replication, shorten the period of treatment with lamivudine, reduce the mutation rate of YMDD and prevent the rebound of HBV after drug withdrawal. Lamivudine 176-186 interferon alpha 1 Homo sapiens 59-62 15510896-1 2004 UNLABELLED: The aim of the study was evaluation the HBeAg/antiHBe seroconversion frequency as a result of lamivudine treatment in children who are nonresponders to previous IFN-alpha therapy. Lamivudine 106-116 interferon alpha 1 Homo sapiens 173-182 15510896-9 2004 CONCLUSIONS: The HBeAg/antiHBe seroconversion rate after one year trial of lamivudine in children with chronic hepatitis B unresponsive to previous IFN alpha therapy was 10%. Lamivudine 75-85 interferon alpha 1 Homo sapiens 148-157 15340535-0 2004 [IFN or oxymatrine in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B]. Lamivudine 67-77 interferon alpha 1 Homo sapiens 1-4 15340535-7 2004 CONCLUSION: These data indicated that IFN or oxymatrine in combination with ongoing lamivudine therapy provided effective antiviral therapy in patients with lamivudine-resistant HBV. Lamivudine 157-167 interferon alpha 1 Homo sapiens 38-41 15340535-8 2004 The addition of IFN or oxymatrine to ongoing lamivudine therapy in lamivudine-resistant patients led to significant inhibition of viral replication and improvement in liver function after 6 months of therapy. Lamivudine 45-55 interferon alpha 1 Homo sapiens 16-19 15340535-8 2004 The addition of IFN or oxymatrine to ongoing lamivudine therapy in lamivudine-resistant patients led to significant inhibition of viral replication and improvement in liver function after 6 months of therapy. Lamivudine 67-77 interferon alpha 1 Homo sapiens 16-19 12584227-3 2003 We investigated the durability of response following IFN, lamivudine, or IFN-lamivudine combination therapy in a meta-analysis of individual patient data. Lamivudine 77-87 interferon alpha 1 Homo sapiens 73-76 12753143-15 2003 However, no mutations were found that have been linked to lamivudine escape, indicating that lamivudine therapy would be effective in IFN-alpha non-responder patients. Lamivudine 93-103 interferon alpha 1 Homo sapiens 134-143 12773249-3 2003 RESULTS: At the end of treatment, the HBV DNA undetectable rate in LAM+IFN group (90.0%) was much higher than that in LAM group (80.0%) and IFN group (46.7%) (chi2 = 13.017, P < 0.001). Lamivudine 67-70 interferon alpha 1 Homo sapiens 71-74 12875729-3 2003 IFN + lamivudine therapy began to be used in the cases who were unresponsive to IFN treatment. Lamivudine 6-16 interferon alpha 1 Homo sapiens 80-83 12584227-9 2003 CONCLUSIONS: The durability of HBeAg seroconversion following lamivudine treatment was significantly lower than that following IFN or IFN-lamivudine combination therapy. Lamivudine 138-148 interferon alpha 1 Homo sapiens 134-137 12139566-1 2002 BACKGROUND: Lamivudine is a new alternative therapeutic agent for chronic hepatitis B, in which alpha interferon (IFN-alpha) monotherapy is not successful enough. Lamivudine 12-22 interferon alpha 1 Homo sapiens 114-123 12121506-2 2002 The efficacy of combination therapy to enhance the immunomodulatory effect of IFN by combining granulocyte-macrophage colony-stimulating factor (GMCSF) or decreasing viral load by adding an antiviral agent such as lamivudine was evaluated prospectively. Lamivudine 214-224 interferon alpha 1 Homo sapiens 78-81 11672823-3 2001 To explore whether there is an additional benefit of combining these two drugs, we reviewed the literature on lamivudine-IFN combination therapy in comparison to the two monotherapies in compensated, HBeAg-positive, CHB patients. Lamivudine 110-120 interferon alpha 1 Homo sapiens 121-124 12121506-12 2002 CONCLUSIONS: The combination of IFN plus GMCSF or lamivudine was effective in non-responders to IFN monotherapy. Lamivudine 50-60 interferon alpha 1 Homo sapiens 96-99 12483247-8 2002 CONCLUSIONS: The efficacy of IFN in controlling virological breakthroughs and exacerbation of hepatitis by infection with lamivudine-resistant HBV mutants in patients with HBeAg-positive chronic hepatitis B could enhance the versatility of lamivudine, which may have to be given to them indefinitely. Lamivudine 122-132 interferon alpha 1 Homo sapiens 29-32 12483247-8 2002 CONCLUSIONS: The efficacy of IFN in controlling virological breakthroughs and exacerbation of hepatitis by infection with lamivudine-resistant HBV mutants in patients with HBeAg-positive chronic hepatitis B could enhance the versatility of lamivudine, which may have to be given to them indefinitely. Lamivudine 240-250 interferon alpha 1 Homo sapiens 29-32 12046342-1 2002 AIMS: The primary objective of this study was to determine the efficacy and safety of lamivudine (LAM) therapy in patients with chronic HBV infection and contraindications to IFN therapy, nonresponders to IFN and patients with advanced liver fibrosis. Lamivudine 86-96 interferon alpha 1 Homo sapiens 175-178 12046342-1 2002 AIMS: The primary objective of this study was to determine the efficacy and safety of lamivudine (LAM) therapy in patients with chronic HBV infection and contraindications to IFN therapy, nonresponders to IFN and patients with advanced liver fibrosis. Lamivudine 98-101 interferon alpha 1 Homo sapiens 175-178 12046342-14 2002 CONCLUSIONS: The results indicate that monotherapy with lamivudine (150 mg daily) for 48 weeks induces sustained inhibition of viral replication and normalisation of transminases in majority of patients with chronic HBV infection who did not respond to IFN, had contraindications to IFN therapy, and in those who had advanced liver fibrosis. Lamivudine 56-66 interferon alpha 1 Homo sapiens 253-256 12046342-14 2002 CONCLUSIONS: The results indicate that monotherapy with lamivudine (150 mg daily) for 48 weeks induces sustained inhibition of viral replication and normalisation of transminases in majority of patients with chronic HBV infection who did not respond to IFN, had contraindications to IFN therapy, and in those who had advanced liver fibrosis. Lamivudine 56-66 interferon alpha 1 Homo sapiens 283-286 11966945-7 2002 In the short term, the introduction of lamivudine is expected to result in almost 3.5 times more CHB patients receiving therapy (lamivudine or IFN-alpha) compared to IFN-alpha only (67% compared to 20%, respectively). Lamivudine 39-49 interferon alpha 1 Homo sapiens 143-152 11672823-5 2001 Candidates for lamivudine-IFN combination therapy were, previously untreated, patients with moderately elevated alanine aminotransferase (ALT). Lamivudine 15-25 interferon alpha 1 Homo sapiens 26-29 11672823-10 2001 Further clinical research on lamivudine-IFN combination therapy appears warranted. Lamivudine 29-39 interferon alpha 1 Homo sapiens 40-43 10861649-10 2000 In conclusion, lamivudine is more suitable than IFN for a broad range of patients, including those with severe liver disease, recurrent flares, pre-core mutant HBV and those who have failed previously IFN treatment or are immunosuppressed. Lamivudine 15-25 interferon alpha 1 Homo sapiens 201-204 11526544-9 2001 In conclusion, the results of this pilot study suggest that sequential treatment with lamivudine and IFN-alpha can induce a sustained virologic response, including HBs seroconversion, in patients with chronic hepatitis B not responding to IFN-alpha alone, without the selection of drug-resistant mutants. Lamivudine 86-96 interferon alpha 1 Homo sapiens 239-248 11038017-5 2000 This case suggests that lamivudine would be an appropriate alternative to IFN, particularly in patients infected with HBV containing an excess of precore mutants resistant to IFN therapy. Lamivudine 24-34 interferon alpha 1 Homo sapiens 175-178 10861651-4 2000 Lamivudine is effective in patients who are interferon (IFN) alpha naive and in those who have failed to respond to IFN alpha, and it suppresses HBV in decompensated liver disease and in liver transplantation. Lamivudine 0-10 interferon alpha 1 Homo sapiens 44-66 10861651-4 2000 Lamivudine is effective in patients who are interferon (IFN) alpha naive and in those who have failed to respond to IFN alpha, and it suppresses HBV in decompensated liver disease and in liver transplantation. Lamivudine 0-10 interferon alpha 1 Homo sapiens 116-125 10689749-6 2000 Indications for lamivudine monotherapy are patients with chronic hepatitis B in which interferon (IFN) is contraindicated or patients who did not respond to a previous course of interferon. Lamivudine 16-26 interferon alpha 1 Homo sapiens 86-96 10689749-6 2000 Indications for lamivudine monotherapy are patients with chronic hepatitis B in which interferon (IFN) is contraindicated or patients who did not respond to a previous course of interferon. Lamivudine 16-26 interferon alpha 1 Homo sapiens 98-101 10689749-6 2000 Indications for lamivudine monotherapy are patients with chronic hepatitis B in which interferon (IFN) is contraindicated or patients who did not respond to a previous course of interferon. Lamivudine 16-26 interferon alpha 1 Homo sapiens 178-188 9623272-3 1998 Lamivudin, famciclovir and the association of ribavirin and IFN are the more relevant and will be clinically accepted in an immediate future. Lamivudine 0-9 interferon alpha 1 Homo sapiens 46-63 34960758-5 2021 We also demonstrated that IFNalpha combinations with sofosbuvir, telaprevir, NITD008, ribavirin, pimodivir, or lamivudine were effective against HCV, HEV, FLuAV, or HIV at lower concentrations, compared to monotherapies. Lamivudine 111-121 interferon alpha 1 Homo sapiens 26-34